| 2025-11-13 |
详情>>
股本变动：
变动后总股本160.33万股
|
| 2025-11-13 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-7.22美元,归母净利润-910.68万美元,同比去年增长-20.68%
|
| 2025-10-10 |
复牌提示：
2025-10-10 11:43:29 停牌，复牌日期 2025-10-10 11:48:29
|
| 2025-08-13 |
详情>>
业绩披露：
2025年中报每股收益-8.82美元,归母净利润-675.95万美元,同比去年增长-79.67%
|
| 2025-06-16 |
详情>>
拆分方案：
每25.0000合并分成1.0000股
|
| 2025-05-08 |
详情>>
业绩披露：
2025年一季报每股收益-0.3美元,归母净利润-305.3万美元,同比去年增长-76.37%
|
| 2025-03-31 |
股东大会：
将于2025-05-09召开股东大会
会议内容 ▼▲
- 1.Elect five directors named in the attached Proxy Statement to serve until the 2026 Annual Meeting of Stockholders.
2.To ratify appointment of Forvis Mazars, LLP as the Company’s independent auditor for the fiscal year ending December 31, 2025.
3.To approve (on an advisory basis) the Company’s executive compensation.
4.To authorize the Board of Directors to amend the Company’s amended and restated certificate of incorporation to effect a reverse stock split of the Company’s issued and outstanding common stock by a ratio in the range of 1-for-3 to 1-for-10 (the “Reverse Stock Split”).
5.To approve the first amendment to the Shuttle Pharmaceuticals Holdings, Inc. 2018 Equity Incentive Plan to increase the amount of shares reserved for issuance by 5,000,000 shares of common stock.
6.To transact any other business as may properly be presented at the Annual Meeting or any adjournment thereof.
|
| 2025-02-26 |
详情>>
业绩披露：
2024年年报每股收益-3.19美元,归母净利润-914.48万美元,同比去年增长-38.71%
|
| 2024-12-31 |
详情>>
内部人交易：
Schafer Joshua等共交易3笔
|
| 2024-11-13 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-3.45美元,归母净利润-754.63万美元,同比去年增长-52.38%
|
| 2024-09-04 |
详情>>
业绩披露：
2024年一季报每股收益-0.83美元,归母净利润-173.1万美元,同比去年增长-77.52%
|
| 2024-09-04 |
详情>>
业绩披露：
2024年中报每股收益-1.8美元,归母净利润-376.22万美元,同比去年增长-19.08%
|
| 2024-09-04 |
详情>>
业绩披露：
2023年年报每股收益-3.53美元,归母净利润-659.27万美元,同比去年增长2.29%
|
| 2024-08-13 |
详情>>
拆分方案：
每8.0000合并分成1.0000股
|
| 2024-06-20 |
股东大会：
将于2024-07-31召开股东大会
会议内容 ▼▲
- 1.Elect six (6) directors named in the attached Proxy Statement to serve until the 2025 Annual Meeting of Stockholders.
2.To ratify appointment of Forvis Mazars LLP as the Company’s independent auditor for the fiscal year ending December 31, 2024.
3.To approve (on an advisory basis) the Company’s executive compensation.
4.To authorize the Board of Directors to amend the Company’s amended and restated certificate of incorporation to effect a reverse stock split of the Company’s issued and outstanding common stock by a ratio in the range of 1-for-3 to 1-for-8 (the “Reverse Stock Split”).
5.To transact any other business as may properly be presented at the Annual Meeting or any adjournment thereof.
|
| 2023-11-13 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.34美元,归母净利润-495.22万美元,同比去年增长-110.86%
|
| 2023-10-20 |
股东大会：
将于2023-12-18召开股东大会
会议内容 ▼▲
- 1.Elect six (6) Directors named in the attached Proxy Statement to serve until the 2024 Annual Meeting of Stockholders.
2.To ratify appointment of FORVIS LLP as the Company’s independent auditor for the fiscal year ending December 31, 2023.
3.To approve (on an advisory basis) the Company’s executive compensation.
4.To transact any other business as may properly be presented at the Annual Meeting or any adjournment thereof.
|
| 2023-08-14 |
详情>>
业绩披露：
2023年中报每股收益-0.23美元,归母净利润-315.95万美元,同比去年增长-137.44%
|
| 2022-11-21 |
股东大会：
将于2022-12-16召开股东大会
会议内容 ▼▲
- 1.Elect six (6) Directors named in the attached Proxy Statement to serve until the 2023 Annual Meeting of Shareholders.
2.To ratify appointment of BF Borgers CPA, PC as the Company’s independent auditors for the fiscal year ended December 31, 2022.
3.To approve (on an advisory basis) the Company’s executive compensation.
4.To approve (on an advisory basis) the frequency of advisory votes on the Company’s executive compensation.
5.To transact any other business as may properly be presented at the Annual Meeting or any adjournment thereof.
|
| 2021-03-15 |
热点提醒：
美股今天进入夏令时交易，盘前交易开始时间提前至北京时间16：00
|